In a recently released analyst research report, Ladenburg Thalmann Financial Services Inc. (NYSE:LTS) Managing Director and Senior Biopharmaceuticals Equity Research Analyst, Michael Higgins, reiterated his bullish stance on shares of cannabinoid biotechnology innovator Intec Pharma Ltd. (NASDAQ:NTEC) with a continued buy rating and a higher price target.
The catalyst lifting Intec’s price target higher at Ladenburg is Intec Pharma’s recently released preliminary results from a Parkinson’s study.
Raised from $12 USD per share, Michael Higgins’s new price target of $15 USD per share implies a potential upside of approximately 75.64% based on the last traded price of $8.54 USD on the NASDAQ.
Be sure to subscribe to updates here so you never miss an important development.
Get Real-Time Updates from MJobserver.com